1. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2022) Authors: Knight, Elia M Pestana; Amin, Sam; Bahi-Buisson, Nadia; Benke, Tim A; Cross, J Helen; Demarest, Scott T; Olson, Heather E; Specchio, Nicola; Fleming, Thomas R; Aimetti, Alex A; Gasior, Maciej; Devinsky, Orrin; Belousova, Elena; Belyaev, Oleg; Ben-Zeev, Bruria; Brunklaus, Andreas; Ciliberto, Micha... Journal: Lancet neurology Issue: Volume 21:Issue 5(2022) Page Start: 417 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗